Year Founded
2016
Ownership
Public
Employees
~50
Therapeutic Areas
GastroenterologyOncologyImmunology
Stage
Phase 1
Modalities
Autologous cell therapy

Carisma Therapeutics General Information

Lead program CT-1119 (CAR-Monocyte) in Phase 1 for mesothelin-positive solid tumors. Multiple preclinical programs in development.

Contact Information

Website
Primary Industry
Biotech
Corporate Office

Drug Pipeline

CT-1119
Phase 1
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Carisma Therapeutics's pipeline data

Book a demo

Key Partnerships

Moderna Therapeutics, University of Pennsylvania

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Carisma Therapeutics Funding

Deal TypeDateAmountStatusStage
Later Stage VCSep 21, 2022$30.0MCompletedPhase 1
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Carisma Therapeutics's complete valuation and funding history, request access »

Carisma Therapeutics Licensing Deals

AssetLicenseeDateTherapeutic Area
GPC3 CAR-MModernaJan 1, 2022Oncology
GPC3-targeted CAR-MModernaJan 17, 2022Oncology
GPC3-targeted CAR-M therapyModernaJan 1, 2022Oncology
You're viewing 2 of 3 licensing deals. Get the full list »

Carisma Therapeutics Investors

AbbVie Ventures
Investor Type: Venture Capital
Holding: Minority
HealthCap
Investor Type: Venture Capital
Holding: Minority
Wellington Partners Life Sciences Venture Capital Fund III LP
Investor Type: Venture Capital
Holding: Minority
Investor Name
Investor Type
Holding
Investor Name
Investor Type
Holding
You're viewing 3 of 4 investors. Get the full list »